Fulcrum Therapeutics (FULC) vs Vogenx (VOGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Fulcrum Therapeutics is the larger company by market cap ($287.3 million vs $258.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FULC | VOGX |
|---|---|---|
| Share price | $3.77 | $17.37 |
| Market cap | $287.26M | $258.03M |
| 1-day change | +0.40% | -0.69% |
| YTD return | -66.84% | — |
| 1-year return | -61.06% | — |
| 5-year return | -85.58% | — |
| EPS (TTM) | $-1.21 | $-0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.74 | $38.41 |
| 52-week low | $2.83 | $12.95 |
| Distance from 52-week high | -76.08% | -54.78% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | -2.52% | +216.64% |
| Average volume | 1.54M | 187.66K |
| Shares outstanding | 76.30M | 14.86M |
| Employees | 9 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Fulcrum Therapeutics
FULC stock →Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About Vogenx
VOGX stock →Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
FULC vs VOGX FAQ
Which is bigger, Fulcrum Therapeutics or Vogenx?
Fulcrum Therapeutics (FULC) is larger, with a market capitalization of $287.26M compared with $258.03M for Vogenx (VOGX).
Are Fulcrum Therapeutics and Vogenx in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.